Dazu eignen sich die Phytochemicals gut. Sie haben zusätzlich ein hohes Potenzial als sehr potente Antioxidantien, als Immunmodulatoren, als Antiphlogistika, und viele weitere wichtige Funktionen. Sie wirken sich nicht nur hinsichtlich der Knochengesundheit aus (Reduktion der arthritischen und den Knochenstoffwechsel beeinträchtigenden Prozesse), sondern auch bei der Risikosenkung und Verbesserung der Therapie von vielen chronischen Erkrankungen.

Interessenkonflikt: Keine angegeben

Korrespondenzadresse

Gast-Prof. Dr. med. Werner Seebauer
The New European Surgical Academy
Unter den Linden 21
10117 Berlin

WSeebauer@nesacademy.org

Literatur

1. Dawson-Hughes B, Mithal A, Bonjour JP et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int. 2010; 21: 1151–4

2. Linseisen J., Bechthold A., Bischoff-Ferrari HA et al.: Vitamin D und Prävention ausgewählter chronischer Krankheiten – Stellungnahme. Deutsche Gesellschaft für Ernährung (Hrsg.), Bonn 2011; aus DGE Diätetik kompakt online Info 2014; S. 130–137

3. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B et al. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int. 2010; 21: 1121–32

4. Engelsen O, Brustad M, Aksnes L, Lund E. Daily duration of vitamin D synthesis in human skin with relation to latitude, total ozone, altitude, ground cover, aerosols and cloud thickness. Photochem Photobiol 2005; 81: 1287–90

5. Kimlin MG, Downs NJ, Parisi AV. Comparison of human facial UV exposure at high and low latitudes and the potential impact on dermal vitamin D production. Photochem Photobiol Sci 2003; 2: 370–5

6. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911–30. Erratum in: J Clin Endocrinol Metab. 2011; 96: 3908

7. Holick MF. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr. 1995; 61 (3 Suppl): 638S–645S.

8. Herrmann M, Kraenzlin M, Pape G, Sand-Hill M, Herrmann W. Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women. Clin Chem Lab Med. 2005; 43: 1118–23

9. Gerdhem P, Ivaska KK, Isaksson A et al. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res. 2007; 22: 127–34

10. Stanger O, Dierkes J, Fowler B, Geisel J, Herrmann W, Pietrzik K, Weger Konsensuspapier der D.A.C.H.-Liga-Homocystein über den rationellen klinischen Umgang mit Homocystein Folsäure und B-Vitaminen bei kardiovaskulären und thrombotischen Erkrankungen – Richtlinien und Empfehlungen M Journal für Kardiologie – Austrian Journal of Cardiology 2003; 10: 190–199

11. DACH-Liga-Homocystein http://www.dach-liga-homocystein.org

12. Mischke M, Plösch T. More than just a gut instinct-the potential interplay between a baby’s nutrition, its gut microbiome, and the epigenome. Am J Physiol Regul Integr Comp Physiol. 2013; 304: R1065–9

13. Hill MJ. Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev. 1997; 6 Suppl 1: S43–5

14. Andrès E, Vogel T, Federici L, Zimmer J, Kaltenbach G. Update on oral cyanocobalamin (vitamin B12) treatment in elderly patients. Drugs Aging. 2008; 25: 927–32

15. Bor MV, von Castel-Roberts KM, Kauwell GPet al. Daily intake of 4 to 7 microg dietary vitamin B-12 is associated with steady concentrations of vitamin B-12-related biomarkers in a healthy young population. Am J Clin Nutr. 2010; 91: 571–7

16. van Wijngaarden JP, Swart KM, Enneman AWet al. Effect of daily vitamin B-12 and folic acid supplementation on fracture incidence in elderly individuals with an elevated plasma homocysteine concentration: B-PROOF, a randomized controlled trial. Am J Clin Nutr. 2014; 100: 1578–86

17. Gommans J, Yi Q, Eikelboom JW, Hankey GJ, Chen C, Rodgers H; VITATOPS trial study group. The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial. BMC Geriatr. 2013; 3:13: 88

18. B-Vitamin Treatment Trialists’ Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006; 151: 282–7

19. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 2006; 333: 1114–7

20. Bønaa KH, Njølstad I, Ueland PM et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006; 354: 1578–88

21. Zhang C, Chi FL, Xie TH, Zhou YH. Effect of B-vitamin supplementation on stroke: a meta-analysis of randomized controlled trials. PLoS One. 201325; 8: e81577

22. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis. Stroke 2010; 41: 1205–12

23. Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev. 2008; 4: CD004514